Loading clinical trials...

Vitamin C and Hiprex in rUTI | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Vitamin C and Hiprex in rUTI

Does Vitamin C Improve the Efficacy of Methenamine Hippurate (Hiprex®) in Prophylaxis of Recurrent Urinary Tract Infections? A Proof of Concept Study

NCT06710899•University Hospitals of North Midlands NHS Trust

View on ClinicalTrials.gov

Summary

A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Female
•Age ≥18 years
•Recurrent proven UTI, defined as "two or more proven infections in six months or three or more infections in six months"
•Willing and able to give fully informed consent
•Patients suitable for prophylaxis following discussion with their clinician.
•No contra-indications to treatment with methenamine hippurate or Vitamin C
•All women will have undergone standard diagnostic work-up and have followed routine conservative UTI prevention measures.
•A working email address to be used to submit urine pH results
•Willing and able to comply with the study procedures
•Females of childbearing potential must be willing to use a highly effective method of contraception (hormonal or barrier method of birth control; abstinence; sterilisation or vasectomised partner)

Exclusion Criteria

•Males
•Women who are pregnant or breast-feeding
•Contraindications to methenamine hippurate as described in BNF: known allergy, gout, severe metabolic acidosis, severe dehydration, eGFR less than 10 ml/min, severe hepatic impairment
•Currently using vitamin C containing supplement or cranberry extract tablets
•Women using urinary alkalinisation agents, e.g potassium citrate, sodium bicarbonate
•Currently receiving any form of bladder instillation or intradetrusor Onabotulinum Toxin A injections
•Patients already on low-dose antibiotics or methenamine hippurate (due to delay that will be incurred by 3-month washout period)
•Indwelling urinary catheter in situ or performing clean intermittent self-catheterisation
•Correctable urinary tract abnormalities, e.g., urinary tract calculi, urinary retention
•Formation of ileal conduit or augmented bladder
+2 more criteria

Locations (1)

University Hospitals of North Midlands NHS Trust

Stoke-on-Trent, Staffordshire, United Kingdom

Key Dates

Start Date

January 1, 2027

Primary Completion Date

August 1, 2027

Completion Date

January 1, 2028

Last Updated

February 11, 2026

Enrollment

ESTIMATED participants

Conditions

Urinary Tract Infections

Interventions

Methenamine Hippurate 1g BD

DRUG

Methenamine Hippurate 1g BD + Vitamin C 1g BD

DRUG

Contacts

Aviva Ogbolosingha

CONTACT

01782 675380 aviva.ogbolosingha@uhnm.nhs.uk

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340

Urinary Tract Infections

View study

RECRUITINGNA

Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections

NCT07233473

Urinary Tract Infections (UTIs)

View study

RECRUITING

Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Vitamin C and Hiprex in rUTI

Inclusion Criteria

Exclusion Criteria

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections

Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children

Ureteral Stent Exchange Abstention in Urinary Tract Infections

Vaginal Ecosystem and Network in the United States Study

PRObiotics for KIdney Transplantation